Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
P/E Ratio
--
P/B Ratio
0.77
Industry P/E
--
Debt to Equity
--
ROE
-1.64 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-166.65 Mln
EBITDA
$-182.18 Mln
Net Profit
$-194.32 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Salarius Pharmaceuticals (SLRX)
| -62.49 | -22.97 | -74.35 | -82.51 | -78.58 | -64.51 | -69.86 |
|
BSE Sensex
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Salarius Pharmaceuticals (SLRX)
| -64.31 | -57.52 | -87.66 | -45.49 | -75.93 | -54.17 | -90.42 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 35.59 | 9,973.38 | 20.56 | 23.13 | |
| 288.99 | 8,956.07 | 23.48 | 58.42 | |
| 25.13 | 9,559.25 | -- | -28.77 | |
| 100.68 | 10,030.35 | 30.81 | 14.16 |
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase... I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas. Address: 2450 Holcombe Blvd., Houston, TX, United States, 77021 Read more
CEO, President & Director
Mr. David J. Arthur M.B.A.
CEO, President & Director
Mr. David J. Arthur M.B.A.
Headquarters
Houston, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Salarius Pharmaceuticals Inc (SLRX) stood at $ 3 Mln as on 31-Dec-24
The share price of Salarius Pharmaceuticals Inc (SLRX) is $0.69 (NASDAQ) as of 21-Apr-2025 16:10 EDT. Salarius Pharmaceuticals Inc (SLRX) has given a return of -78.58% in the last 3 years.
Salarius Pharmaceuticals Inc (SLRX) has a market capitalisation of $ 1 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Salarius Pharmaceuticals Inc (SLRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Salarius Pharmaceuticals Inc (SLRX) and enter the required number of quantities and click on buy to purchase the shares of Salarius Pharmaceuticals Inc (SLRX).
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas. Address: 2450 Holcombe Blvd., Houston, TX, United States, 77021
The CEO & director of Mr. David J. Arthur M.B.A.. is Salarius Pharmaceuticals Inc (SLRX), and CFO & Sr. VP is Mr. David J. Arthur M.B.A..
There is no promoter pledging in Salarius Pharmaceuticals Inc (SLRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Salarius Pharmaceuticals Inc. (SLRX) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Salarius Pharmaceuticals Inc (SLRX) was $0 Mln.
$0.01
(
